Avoiding rash decisions about zoster vaccination: insights from cost-effectiveness evidence

de Boer and colleagues present a cost-effectiveness analysis based in the Netherlands of two vaccines available for the prevention of herpes zoster. Zostavax® was the first vaccine available for the prevention of herpes zoster in older adults. A live-attenuated vaccine, Zostavax is not free of limit...

Descripción completa

Detalles Bibliográficos
Autores principales: Good, Chester B., Parekh, Natasha, Hernandez, Inmaculada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298010/
https://www.ncbi.nlm.nih.gov/pubmed/30558674
http://dx.doi.org/10.1186/s12916-018-1231-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298010/
https://www.ncbi.nlm.nih.gov/pubmed/30558674
http://dx.doi.org/10.1186/s12916-018-1231-3

Ejemplares similares